Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

151.73 +1.72 (+1.15%)
Official Closing Price Updated: 4:10 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Earnings Scheduled For May 7, 2025
Via Benzinga
Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect
Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results tomorrow before the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?
Via Benzinga
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead? 
Via MarketBeat
Topics ETFs Economy Government
Explore the top gainers and losers within the S&P500 index in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday. 
Via Chartmill
Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?
Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially... 
Via Benzinga
Topics World Trade
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Which S&P500 stocks are moving on Friday?
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday?
Wall Street bounced back from early losses, driven by upbeat bank earnings and cooler inflation data, while shrugging off trade war concerns. 
Via Benzinga
Topics Economy World Trade
FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened
JPMorgan, which holds a ‘Neutral’ rating on the stock, opined that Charles River could see disruption from customers reassessing its preclinical strategies in the near term. 
Via Stocktwits
Topics Animal Testing
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency. 
Via Benzinga
Topics Animal Testing Artificial Intelligence
These S&P500 stocks that are showing activity before the opening bell on Friday.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
Charles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Via Benzinga
Tuesday's session: top gainers and losers in the S&P500 index
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Demystifying Charles River: Insights From 10 Analyst Reviews
Via Benzinga
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Exploring the top movers within the S&P500 index during today's session.
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Top S&P500 movers in Thursday's session
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Which S&P500 stocks are gapping on Thursday?
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
3 Reasons CRL is Risky and 1 Stock to Buy Instead
Over the last six months, Charles River Laboratories’s shares have sunk to $173.44, producing a disappointing 15.7% loss while the S&P 500 was flat. This might have investors contemplating their next... 
Via StockStory
Topics Stocks
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.